Product Description
Meprobamate is used to treat anxiety disorders or for short-term relief of the symptoms of anxiety in adults and children 6 years of age and older. Meprobamate is in a class of medications called tranquilizers. It works by slowing activity in the brain to allow for relaxation. (Sourced from: https://medlineplus.gov/druginfo/meds/a682077.html)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous,Intraocular
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Brazil | Canada | Chile | Egypt | Ireland | Lebanon | Morocco | New Zealand | Pakistan | Portugal | South Africa | Taiwan | Thailand | Tunisia | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/05/2025 |
News Article |
Viñas Queirolo Wins Big at the 2025 San Francisco Wine and Spirits Competition |
|
03/26/2025 |
News Article |
NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
|
02/17/2025 |
News Article |
GREAT SPRING BREAK DISCOVERIES AT ESPACE POUR LA VIE |
|
01/28/2025 |
News Article |
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 |